Sutter Health Research Enterprise
3838 California Street
San Francisco, CA, 94118
(415) 751-1847
ClinicalResearch@sutterhealth.org
Sutter Health Research Enterprise
3838 California Street
San Francisco, CA, 94118
(415) 751-1847
ClinicalResearch@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Locally Advanced or Metastatic (Immunogen Soraya)
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial
Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Fola
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD, Karolina Harger N.P.
Status: Active, Recruiting
Locally Advanced or Metastatic (Roche YO40482)
Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab
to Patients With Advanced Platinum-sensitive Ovarian Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Metastatic (Sutro STRO-002-GM1)
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRa) Antibody Drug Conjugate in
Ovarian & Endometrial Cancers
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Metastatic or Locally Advanced (Agenus GOG 3028) (Temp Enrollment Hold)
Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line
Cervical Cancer
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Not Recruiting
Novocure Innovate3
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel
for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / IN
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD
Status: Active, Recruiting